AstraZeneca plc is set to test in a global clinical trial the potential of its blood cancer drug Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) related to coronavirus infection in severely ill patients. Calquence is a next-generation, highly selective Bruton's tyrosine kinase (BTK) inhibitor currently used to treat certain types of blood cancers.
from RTT - Biotech https://ift.tt/2xtsP2G
via IFTTT
No comments:
Post a Comment